Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a cross-sectional and an observational study, investigator-initiated study in HER2-low breast cancer patients. Approximately 255 subjects with HRD (homologous recombination deficiency) assessment will be enrolled in this study to examine the distribution and features of HRD/HRR (homologous recombination repair).
In this study, investigators plan to clarify the frequency of HRR/HRD in Chinese patients with HER2-low breast cancer.
In addition, it is planned to investigate any association between invasive disease-free survival (iDFS)/overall survival (OS) and HRD/HRR in HER2-low breast cancer patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental ARM | All patients received standard care for postoperative management. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Standard Management | Other | Standard Management |
|
| Measure | Description | Time Frame |
|---|---|---|
| 1.To assess the distribution characteristics of mHRR/HRD in breast cancer with low HRE2 expression in Chinese population | the distribution and features of HRD /HRR is evaluated. | At the time of 4 weeks after surgery |
| Measure | Description | Time Frame |
|---|---|---|
| To assess the clinical characteristics between patients with mutations and non-mutation | Association between mutations and non-mutations group in HRD/HRR is assessed. | At the time of 4 weeks after surgery |
| To compare the correlation between iDFS/OS and different adjuvant treatment regimens for breast cancer with low HER2 expression |
Not provided
Inclusion Criteria:
5）Absence of distant metastasis; 6）Availability of adequate tumor tissue and blood samples for biomarker analysis.
Exclusion Criteria:
Not provided
Not provided
Female patients aged 18-70 years with pathologically confirmed HER2-low breast cancer (defined as IHC 2+/ISH- or IHC 1+ per ASCO/CAP guidelines)
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Gong Chang, doctor | Contact | 02034070499 | changgong282@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Gong Chang, doctor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | Guangzhou | Guangdong | 510120 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
IDFS, was a composite endpoint defined as the time from enrollment until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site); Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer. 3-year Overall survival (OS) was defined as time from date of randomization to death from any cause, otherwise cases were censored at date last known to be alive. Association between IDFS/OS and HRD/HRR information is evaluated. |
| At the time of 36 months after surgery |
| To investigate the HRR/HRD characteristics and clinical characteristics (family history, age pathological feature es, etc.) of breast cancer patients with low HER2 expression | Association between multivariate prognostic factors and survival is evaluated. | At the time of 4 weeks after surgery |
| D017437 |
| Skin and Connective Tissue Diseases |